Moxidectin for scabies: clinical study updates

‍Moxidectin for scabies: clinical study updates

The first ever clinical trial of moxidectin in humans with scabies, a Phase 2a dose finding study [protocol number MDGH-MOX-2001; NCT03905265] of single oral doses of moxidectin in adults with scabies, was completed in February 2022. Start-up activities for a Phase 2b dose confirmatory study are underway. This would be a multicentre, multi-country study comparing different doses of moxidectin to one of the current standards of care, ivermectin, with the primary efficacy outcome measuring proportion of subjects with complete cure by Day 28. Primary safety outcomes will include the incidence and severity of adverse events, and laboratory safety parameters.

-End